Nivolumab plus Ipilimumab as first-line therapy in advanced RCC

Nephrology · Oncology · Urology

The management of advanced renal cell carcinoma (aRCC) has evolved considerably with the introduction of targeted therapies and immune checkpoint inhibitors. Nivolumab plus Ipilimumab is an established first-line combination for adults with intermediate- or poor-risk advanced RCC. This approach represents a shift from therapies that primarily inhibit tumor-associated signaling pathways toward treatment that activates the immune system against cancer cells. By targeting distinct immune checkpoint pathways, the combination offers an important treatment option for eligible patients and has become a key component of contemporary aRCC management.[1]Rationale for combination immunotherapyNivolumab is a programmed cell death protein 1 (PD-1) inhibitor that blocks the interaction between PD-1 and its ligands, helping restore T-cell-mediated antitumor activityIpilimumab is a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor that enhances T-cell activation through a complementary immune checkpoint pathwayCombining these agents targets different stages of the immune response and may produce a broader antitumor effect than either agent aloneThis combination provides a first-line immunotherapy option for patients with intermediate- or poor-risk advanced RCC, as specified in the approved indication[1]Indications and patient selectionNivolumab in combination with Ipilimumab is indicated as first-line treatment for adults with intermediate- or poor-risk advanced RCCPatient selection should incorporate disease stage, risk classification, performance status, comorbidities, and suitability for immune checkpoint inhibitionThe combination should be distinguished from other approved Nivolumab-based regimens, including Nivolumab plus Cabozantinib, which represents a separate first-line treatment optionTreatment decisions should account for the potential benefits of combination immunotherapy and the possibility of immune-mediated toxicity[2][3]Dosing and administrationTreatment phaseRecommended regimenCombination inductionNivolumab 3 mg/kg followed by Ipilimumab 1 mg/kg intravenously on the same day, every 3 weeks for 4 dosesMaintenance treatmentAfter completion of 4 combination doses, Nivolumab is continued as a single agent at 240 mg every 2 weeks or 480 mg every 4 weeksAdministration sequenceNivolumab is administered before Ipilimumab during each combination treatment cycleIpilimumab should be administered immediately following Nivolumab on the same treatment day. The combination induction phase is followed by Nivolumab maintenance, according to the prescribing information.[2][3]Treatment progression and sequencing challengesDespite the clinical benefits of combination immunotherapy, disease progression may occur, and some patients may discontinue treatment because of toxicityThe optimal treatment strategy after progression on first-line immune checkpoint inhibitor combinations remains an important clinical challengeEvidence supporting the use of further immune checkpoint inhibitor therapy after progression on prior immunotherapy is limited, particularly because high-level prospective evidence and established sequencing recommendations remain insufficientRetrospective real-world analyses have suggested that selected patients may benefit from subsequent immune checkpoint inhibitor treatment; however, these findings do not establish a standard approachClinical trial participation may help address the unmet need for effective treatment options after progression on first-line immunotherapy[2][3]ConclusionNivolumab plus Ipilimumab is an important first-line immunotherapy option for adults with intermediate- or poor-risk advanced RCC. Its complementary inhibition of PD-1 and CTLA-4 supports a coordinated antitumor immune response. Appropriate patient selection, adherence to the induction and maintenance schedule, and careful assessment of treatment response are essential. Further evidence is needed to establish optimal treatment sequencing after progression on first-line immunotherapy.Reference(s):1. Choueiri TK, Kluger H, George S, et al. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J Immunother Cancer. 2022;10(11):e005780. doi:10.1136/jitc-2022-005780. https://pmc.ncbi.nlm.nih.gov/articles/PMC9639138/2. OPDIVO (nivolumab) injection, for intravenous use. United States Food and Drug Administration. Revised in March, 2022. Accessed on November 11 , 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s112lbl.pdf3. YERVOY(ipilimumab) injection, for intravenous use. United States Food and Drug Administration. Revised in March, 2022. Accessed on November 11 , 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s132lbl.pdf